본문 바로가기

Effects on agitation with rivastigmine patch monotherapy and combination therapy with memantine in mild to moderate Alzheimer's disease: a multicenter 24-week prospective randomized open-label study (the Korean EXelon Patch and combination with mEmantine

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopusSSCI
저널 순위
JCR Q2Scopus Q1
저널
GERIATRICS & GERONTOLOGY INTERNATIONAL17(3) · pp.494 · 2017
피인용
Web of Science 9Scopus 11
FWCI (Scopus)
0.62
JCR IF
JCR 2016 2.351
ISSN
1444-1586

저자

  1. Yoon, Soo J제1저자Department of Neurology, Eulji University Hospital, Eulji University School of Medicine, Daejeon, South Korea
  2. Choi, Seong HDepartment of Neurology, Inha University Hospital, Inha University School of Medicine, Incheon, South Korea
  3. Na, Hae R교신저자Department of Neurology, Bobath Memorial Hospital, Seongnam-si, South Korea
  4. Park, Kyung-WonDepartment of Neurology, Dong-A Medical Center, Dong-A University College of Medicine, Busan, South Korea
  5. 김은주Department of Neurology, Pusan National University Hospital, Pusan National University School of Medicine and Medical Research Institute, Pusan, South Korea
  6. Han, Hyun JDepartment of Neurology, Myongji Hospital, Seonam University of College of Medicine, Goyang, South Korea
  7. Lee, Jae-HongDepartment of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Bucheon, South Korea
  8. Shim, Young SDepartment of Neurology, Bucheon St. Mary's Hospital, The Catholic University College of Medicine, Bucheon, South Korea
  9. Na, Duk LDepartment of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

초록

Aim: Memantine is known to be effective in the treatment of the behavioral symptoms of dementia, especially agitation in moderate to severe Alzheimer's disease (AD). However, memantine and rivastigmine patch combination therapy has not been well studied in determining treatment effectiveness with mild to moderate AD patients. Methods: This was a multicenter, 24-week, prospective, randomized, open-label study design. A total 147 AD patients with Mini-Mental State Examination scores from 10 to 20 were randomly assigned to rivastigmine patch monotherapy and combination therapy with memantine groups. Agitation symptoms, using the Korean Version of the Cohen Mansfield Agitation Inventory were evaluated at baseline and at study end. Suppression and emergence of agitation symptoms were also evaluated. We carried out factor analyses to evaluate the interrelationship of agitation symptoms and to investigate treatment response in these symptoms. Results: Factor analyses showed two symptom clusters: factor A - aggressive agitated behaviors - versus factor B - non-aggressive agitated behaviors. The rivastigmine patch monotherapy group showed significantly decreased factor B scores and had a tendency of decreased Korean Version of the Cohen Mansfield Agitation Inventory total scores and factor A scores. Conversely, the combination therapy group showed significantly increased Korean Version of the Cohen Mansfield Agitation Inventory total scores and factor B scores. Neither monotherapy nor combination therapy reduced the emergence of new agitation symptoms. Conclusions: In this trial of mild to moderate AD patients, the rivastigmine patch monotherapy group experienced a reduction of non-aggressive agitated behaviors. However, combination therapy with memantine did not show any benefit on the agitation associated with mild to moderate AD.

키워드

agitationAlzheimer's diseasememantinerivastigmine patchNEUROPSYCHIATRIC SYMPTOMSBEHAVIORAL SYMPTOMSPSYCHOLOGICAL SYMPTOMSRECEIVING DONEPEZILDEMENTIADISORDERSDEMOGRAPHICSASSOCIATIONMANAGEMENTINVENTORY

식별자

Scopus EID
2-s2.0-84964426838
WoS UID
000399446800017